NEW PERSPECTIVES IN THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Abstract

Nonalcoholic Fatty Liver Disease (NAFLD) has become a growing public health concern due to its high prevalence and direct relationship with obesity, type 2 diabetes, and metabolic syndrome. This study aimed to analyze the new perspectives in the treatment of NAFLD, focusing on pharmacological approaches, lifestyle interventions, and technological innovations applied to diagnosis and treatment, based on publications between 2020 and 2025. The methodology used consisted of a qualitative literature review, with a careful selection of studies in renowned databases. The results showed significant advances in the development of pharmacological therapies, such as GLP-1 receptor agonists and SGLT2 inhibitors, which demonstrated efficacy in reducing hepatic steatosis and improving metabolic parameters. Lifestyle-based interventions, especially the combination of low-calorie diet and exercise, remain key to disease management, although long-term adherence and maintenance pose challenges. In the field of technological innovations, tools such as metabonomics and artificial intelligence applied to early diagnosis have shown promise for the staging and monitoring of NAFLD. It is concluded that the ideal treatment should be multidisciplinary and personalized, integrating pharmacological therapies, behavioral changes, and cutting-edge technologies to improve clinical efficacy and quality of life for patients. It is recommended that studies evaluating the efficacy and safety of these new approaches in diverse populations be continued.